| Description | (Z-Ala-Ala-Ala-Ala)2Rh110 is a sensitive fluorogenic elastase substrate. The colorless and nonfluorescent (Z-Ala-Ala-Ala-Ala)2Rh110 is selectively cleaved by elastase to yield the highly fluorescent compound rhodamine 110, which can be analyzed with an excitation wavelength of 485 nm and emission (Z-Ala-Ala-Ala-Ala)2Rh110 is a sensitive fluorogenic elastase substrate. The colorless and nonfluorescent (Z-Ala-Ala-Ala-Ala)2Rh110 is selectively cleaved by elastase to yield the highly fluorescent compound rhodamine 110, which can be analyzed with an excitation wavelength of 485 nm and emission wavelength of 525 nm... Read More | α-MSH (α-Melanocyte-Stimulating Hormone) TFA, an endogenous neuropeptide, is an endogenous melanocortin receptor 4 (MC4R) agonist with anti-inflammatory and antipyretic activities. α-MSH TFA is a post-translational derivative of pro-opiomelanocortin (POMC)[1][2] | C-Peptide 1 (rat), a peptide, is aβ-catenin/GSK-3β activator. C-Peptide 1 (rat) can regulate the Wnt/β-catenin signaling pathway. C-Peptide 1 (rat) can be used for the research of cancer[1] | Endomorphin 2 TFA, a high affinity, highly selective agonist of the µ-opioid receptor, displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM[1] | Psalmotoxin 1 (PcTx1) is a protein toxin that can bind at subunit-subunit interfaces of acid-sensing ion channel 1a (ASIC1a). Psalmotoxin 1 is a potent and slective ASIC1a inhibitor (IC50: 0.9 nM) by increasing the apparent affinity for H+ of ASIC1a. Psalmotoxin 1 can induce cell apoptosis, also Psalmotoxin 1 (PcTx1) is a protein toxin that can bind at subunit-subunit interfaces of acid-sensing ion channel 1a (ASIC1a). Psalmotoxin 1 is a potent and slective ASIC1a inhibitor (IC50: 0.9 nM) by increasing the apparent affinity for H+ of ASIC1a. Psalmotoxin 1 can induce cell apoptosis, also inhibits cell migration, proferliration and invasion of cancer cells. Psalmotoxin 1 can be used in the research of cancers, or neurological disease[1][3][4][6]... Read More |